Evidence brief · Supplement
NMN for Physical function / insulin sensitivity
Evidence grade C — Early, small
- Overall grade
- Grade C
- Last revised
- 1
- graded outcome
- 0
- references listed
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
1 at grade C — 1 graded row
What is known
Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.
- Physical function / insulin sensitivityEvidence grade C
Early, small
Smallmixed
What is uncertain
Read off the same rows as above. Nothing here is added that the entry does not itself record.
- Thin evidence: Physical function / insulin sensitivity (grade C).
The evidence in words
The verdict
For physical function / insulin sensitivity, NMN earns evidence grade C (small effect, mixed consistency) — the evidence is limited or mixed. Early, small
How it might work
Supplementation raises blood NAD+ and related metabolites, the premise being that restoring NAD+ counters aspects of aging.
How to use it
250–500 mg/day in trials; the field is early and product quality varies.
Safety & cautions
Appears well tolerated short-term; long-term safety uncharacterized.
Bottom line
It reliably raises NAD+, which is not the same as making you healthier or longer-lived. Promising biology, no proven payoff — an experiment, not an answer.
How it is used
As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.
- Standard
- 250–500 mg/day.
Goes with
- NMNRead the full NMN monographEvidence grade C
Related reading
Entries that share this one's tags or conditions.
- Nicotinamide Riboside for Blood NAD+Evidence grade A — Reliably raisedEvidence grade A
- Nicotinamide Riboside for Physical / metabolic functionEvidence grade C — InconsistentEvidence grade C
- NMN for Blood NAD+Evidence grade B — Reliably raisedEvidence grade B
- Nicotinamide RibosideThe better-studied NAD+ precursor — reliably raises NAD+, still short on hard human outcomes.Evidence grade C
Sources
This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.
Last revised . A grade is this entry's reading of the evidence, not medical advice.